Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 1-2, 2010, Pages 187-193

  Nefussy, Beatrice ^a   Artamonov, Irena ^a   Deutsch, Varda ^a   Naparstek, Ela ^a,c   Nagler, Arnon ^b,c   Drory, Vivian E ^a,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

ALS; Granulocyte colony stimulating factor; Haematopoietic stem cells; Mobilization; Motor neuron disease

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALS FUNCTIONAL RATING SCALE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BONE MARROW CELL; BONE PAIN; CELL SUBPOPULATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROSTOMY; HUMAN; MALE; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MYALGIA; OUTCOME ASSESSMENT; PERCUTANEOUS ENTEROGASTROSTOMY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; STEM CELL MOBILIZATION; VITAL CAPACITY;

ACTION POTENTIALS; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; PATIENT DROPOUTS; PILOT PROJECTS; PLACEBOS; TREATMENT FAILURE; VITAL CAPACITY;

EID: 77649323766     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960902933809     Document Type: Article

References (40)

1. Brooks BR, Sanjak M, Belden D, Juhasz-Poscine K, Waclawik A. Natural history of amyotrophic lateral sclerosis: impairment, disability, handicap. In: Brown RH, Meininger V, Swash M, editors. Amyotrophic Lateral Sclerosis. London: Martin Dunitz, 2000. pp. 31-58.
2. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418: 41-9.
3. Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA, et al. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet. 2004;363:1432-7.
4. Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B. Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci. 2003;100:1364-9.
5. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113-7.
6. Yamanaka K, Boillee S, Roberts EA, Garcia ML, McAlonis- Downes M, Mikse OR, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci. 2008;105:7594-9.
7. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389-92.
8. Beers DR, Henkel JS, Xiao Q, ZhaoW,Wang J, Yen AA, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci. 2006;103:16021-6.
9. Corti S, Locatelli F, Donadoni C, Guglieri M, Papadimitriou D, Strazzer S, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain. 2004;127: 2518-32.
10. Ende N, Weinstein F, Chen R, Ende M. Human umbilical cord blood effect on SOD mice (amyotrophic lateral sclerosis). Life Sci. 2000;67:53-9.
11. Garbuzova-Davis S, Willing AE, Zigova T, Saporta S, Justen EB, Lane JC, et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J Hematother Stem Cell Res. 2003;12:255-70.
12. Solomon JN, Lewis CA, Ajami B, Corbel SY, Rossi F, Krieger C. Origin and distribution of bone marrow derived cells in the central nervous system in a mouse model of amyotrophic lateral sclerosis. Glia. 2006;53:744-53.
13. Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res. 2001;10:913-5.
14. Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Oliveri C, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotr Later Scler. 2003;4:158-61.
15. Mazzini L, Maresch K, Ferrero I, Vassallo E, Oliveri G, Nasuelli N, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci. 2008;265:78-83.
16. Appel SH, Engelhardt JL, Henkel JS, Sikols L, Beers DR, Yen AA, et al. Haematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008;71:1326-34.
17. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood. 1996;88:1907-29.
18. Hubel K, Engert A. Clinical applications of granulocytecolony stimulating factor: an update and summary. Ann Hematol. 2003;82:207-13.
19. Schnieder A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The haematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115:2083-98.
20. Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte-colony stimulating factor after focal cerebral ischaemia. Stroke. 2003;34:745-51.
21. Meur M, Pitzer C, Teismann P, Kruger C, Goricke B, Laage R, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem. 2006;97:675-86.
22. Hartung T. Anti-inflammatory effects of granulocyte-colony stimulating factor. Curr Opin Hematol. 1998;5:221-5.
23. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS: a dual role? Exp Neurol. 2004;187: 1-10.
24. Weydt P, Weiss MD, Moller T, Carter GT. Neuroinflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs. 2002;3:1720-4.
25. Pitzer C, Kruger C, Plaas C, Kirsch F, Dittgen T, Muller R, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain. 2008;131:3335-47.
26. Cashman N, Tan LY, Krieger C, Madler B, Mackay A, Mackenzie I, et al. Pilot study of granulocyte-colony stimulating factor (G-CSF): mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve. 2008;37:620-5.
27. Zhang Y, Wang L, Fu Y, Song H, Zhao H, Deng M, et al. Preliminary investigation of effect of granulocyte-colony stimulating factor on amyotrophic lateral sclerosis. Amyotroph Later Scler. 2009 (Epub ahead of print).
28. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Later Scler Other Motor Neuron Disord. 2000;1:293-9.
29. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessment of respiratory function. BDNF ALS Study group (Phase II/III). J Neurol Sci. 1999;169:13-21.
30. Medical Research Council. Aid to the examination of the peripheral nervous system, Memorandum no. 45, Her Majesty's Stationery Office, London, 1976.
31. de Carvalho M, Scotto M, Lopes A, Swash M. Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle Nerve. 2003;28:630-3.
32. Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K. Validity of the McGill Quality of Life questionnaire in the palliative care setting: a multicentre Canadian study demonstrating the importance of the existential domain. Palliat Med. 1997;11:3-20.
33. Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933-5.
34. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007;69:776-84.
35. Gordon PH, Moore DH, Miller RG, Florence JM, Veheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurology. 2007;6:1045-53.
36. de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:17-28.
37. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocytecolony stimulating factor for acute ischaemic stroke: a randomized controlled trial. Can Med Assoc J. 2006;174: 927-33.
38. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique patterns of haematopoietic cell mobilization induced by CXCR4 antagonist 4F-benzoyl- TN14003. Stem Cells. 2007;25:2158-66.
39. Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett S, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modelling ALS. PLoS ONE. 2007;2:1205.
40. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke. 2004;35:2385-9.